Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruby F Meredith

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2010
Renal dosimetryBarry W Wessels, Roger G Dale, Marta Cremonesi, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003E Hammond, Brian A Berkey, Karen K Fu, et al.
International Journal of Radiation Oncology, Biology, Physics|September 5, 2007
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery aloneStephen M Sawrie, Barton L Guthrie, Sharon A Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinomaDavid M Brizel, Barbara A Murphy, David I Rosenthal, et al.
American Journal of Clinical Oncology|December 2, 2016
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-TrastuzumabRuby F Meredith, Julien J Torgue, Tania A Rozgaja, et al.
International Journal of Radiation Oncology, Biology, Physics|March 22, 2008
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatmentJimmy J Caudell, Stephen M Sawrie, Sharon A Spencer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2008
Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancerJimmy J Caudell, Philip E Schaner, Ruby F Meredith, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2003
Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09Jacquelyn Fisher, Charles Scott, Charles W Scarantino, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2006
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapyHazel B Breitz, Richard E Wendt, Michael S Stabin, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinAndres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Cancer Biotherapy & Radiopharmaceuticals|September 30, 2010
Renal dosimetryBarry W Wessels, Roger G Dale, Marta Cremonesi, et al.
International Journal of Radiation Oncology, Biology, Physics|October 8, 2003
P105 as a prognostic indicator in patients irradiated for locally advanced head-and-neck cancer: a clinical/laboratory correlative analysis of RTOG-9003E Hammond, Brian A Berkey, Karen K Fu, et al.
International Journal of Radiation Oncology, Biology, Physics|September 5, 2007
Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery aloneStephen M Sawrie, Barton L Guthrie, Sharon A Spencer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2008
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinomaDavid M Brizel, Barbara A Murphy, David I Rosenthal, et al.
American Journal of Clinical Oncology|December 2, 2016
Safety and Outcome Measures of First-in-Human Intraperitoneal α Radioimmunotherapy With 212Pb-TCMC-TrastuzumabRuby F Meredith, Julien J Torgue, Tania A Rozgaja, et al.
International Journal of Radiation Oncology, Biology, Physics|March 22, 2008
Locoregionally advanced head and neck cancer treated with primary radiotherapy: a comparison of the addition of cetuximab or chemotherapy and the impact of protocol treatmentJimmy J Caudell, Stephen M Sawrie, Sharon A Spencer, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2008
Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancerJimmy J Caudell, Philip E Schaner, Ruby F Meredith, et al.
International Journal of Radiation Oncology, Biology, Physics|June 6, 2003
Phase III quality-of-life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head-and-neck cancer--RTOG 97-09Jacquelyn Fisher, Charles Scott, Charles W Scarantino, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2006
166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapyHazel B Breitz, Richard E Wendt, Michael S Stabin, et al.
Cancer Biotherapy & Radiopharmaceuticals|August 24, 2005
Pretargeted radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion proteinAndres Forero-Torres, Sui Shen, Hazel Breitz, et al.
Pageof 6